Aerie Pharmaceuticals Inc (NASDAQ:AERI) Short Interest Update

Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 13,290,000 shares, a drop of 9.6% from the December 15th total of 14,700,000 shares. Approximately 35.2% of the company’s shares are sold short. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 11.8 days.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its holdings in Aerie Pharmaceuticals by 1.2% during the 3rd quarter. Rhumbline Advisers now owns 58,234 shares of the company’s stock valued at $1,119,000 after purchasing an additional 663 shares in the last quarter. California State Teachers Retirement System grew its holdings in Aerie Pharmaceuticals by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 65,778 shares of the company’s stock valued at $1,264,000 after purchasing an additional 786 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Aerie Pharmaceuticals by 2,330.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,458 shares of the company’s stock valued at $43,000 after purchasing an additional 1,398 shares in the last quarter. Endurance Wealth Management Inc. grew its holdings in Aerie Pharmaceuticals by 173.7% during the 3rd quarter. Endurance Wealth Management Inc. now owns 2,600 shares of the company’s stock valued at $50,000 after purchasing an additional 1,650 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY grew its holdings in Aerie Pharmaceuticals by 21.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 14,064 shares of the company’s stock valued at $270,000 after purchasing an additional 2,488 shares in the last quarter.

AERI has been the topic of a number of recent analyst reports. Stifel Nicolaus cut their price target on shares of Aerie Pharmaceuticals from $77.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright cut their target price on shares of Aerie Pharmaceuticals from $55.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Oppenheimer cut their target price on shares of Aerie Pharmaceuticals from $45.00 to $25.00 in a research note on Thursday, November 7th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, October 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.07.

Shares of AERI stock opened at $24.53 on Thursday. The company’s fifty day simple moving average is $22.62 and its 200-day simple moving average is $22.19. Aerie Pharmaceuticals has a 52 week low of $17.15 and a 52 week high of $50.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 5.43 and a quick ratio of 5.23.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02). The firm had revenue of $18.54 million for the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative net margin of 328.34% and a negative return on equity of 77.63%. As a group, research analysts forecast that Aerie Pharmaceuticals will post -3.89 earnings per share for the current year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Recommended Story: What is included in the gross domestic product?

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.